Filing Details

Accession Number:
0001104659-19-032920
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-05-30 21:27:55
Reporting Period:
2019-05-28
Accepted Time:
2019-05-30 21:27:55
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1761612 Bicycle Therapeutics Plc BCYC Pharmaceutical Preparations (2834) V8
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1114448 Ag Novartis Lichtstrasse 35
Basel V8 CH 4056
No No Yes No
1297709 Ltd Bioventures Novartis C/o Novartis International Ag
Wsj-200.220
Ch-4002 Basel V8 0000000000
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2019-05-28 893,195 $0.00 893,195 No 4 C Direct
Ordinary Shares Acquisiton 2019-05-28 71,450 $0.00 964,645 No 4 X Direct
Ordinary Shares Acquisiton 2019-05-28 636,366 $0.00 1,601,011 No 4 C Direct
Ordinary Shares Acquisiton 2019-05-28 168,630 $14.00 1,769,641 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 X Direct
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Series A Preferred Shares Disposition 2019-05-28 893,195 $0.00 893,195 $0.00
Ordinary Shares Series A Preferred Shares Warrants Disposition 2019-05-28 71,450 $0.00 71,450 $0.00
Ordinary Shares Series B1 Preferred Shares Disposition 2019-05-28 636,366 $0.00 636,366 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 X Direct
0 No 4 C Direct
Footnotes
  1. Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.
  2. Upon conversion of all of the Series B1 Preferred Shares into Ordinary Shares in connection with the Issuer's initial public offering, the Warrants became exercisable for Ordinary Shares. The Warrants had an exercise price of a nominal value per share and were exercised immediately prior to completion of the Issuer's initial public offering.